louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03805958: Ultrasound-guided Combined Spinal-epidural Anesthesia: Pre-procedure Versus Real-time Scan
Official title: A Randomized Comparison of the Ultrasound-guided Combined Spinal-epidural Anesthesia Technique: Pre-procedure Scan Versus Real-time Scan
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Regional Anesthesia Morbidity
Ultrasonography
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2019-01-16
Enrollment: 56
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The investigators will compare the success rate, the consumed time, the number of needle passing, the depth and angle of the needle, the anesthetic effect, complications, pain and patient's satisfaction between 'Real-time scan' and 'Pre-procedure scan', when we performing spinal/epidural combined anesthesia.

Detailed description: Traditionally, spinal/epidural combined anesthesia has been performed by palpation of the landmark like Tuffier's line. There are some studies that using ultrasound improves the success rate to regional anesthesia. There are two methods of using ultrasonography, 'Real-time scan' and 'Pre-procedure scan'. Direct comparison of these two methods is not yet studied. So investigators will compare the success rate, the consumed time, the number of needle passing, the depth and angle of the needle, the anesthetic effect, complications, pain and patient's satisfaction.

Eligibility criteria: Inclusion Criteria:

* Spinal/Epidural combined anesthesia is required.

Exclusion Criteria:

* Skin infection or trauma
* Abnormal coagulation lab
* History of spine surgery
* Pregnancy
* Abnormal structure of spine

Primary outcomes:
measure: Number of needle pass
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: SMG-SNU Boramae hospital
name: Tae Kyong Kim, Kim
role: STUDY_DIRECTOR
References:
citation: Grau T, Leipold RW, Conradi R, Martin E, Motsch J. Ultrasound imaging facilitates localization of the epidural space during combined spinal and epidural anesthesia. Reg Anesth Pain Med. 2001 Jan-Feb;26(1):64-7. doi: 10.1053/rapm.2001.19633. No abstract available.
citation: Kil HK, Cho JE, Kim WO, Koo BN, Han SW, Kim JY. Prepuncture ultrasound-measured distance: an accurate reflection of epidural depth in infants and small children. Reg Anesth Pain Med. 2007 Mar-Apr;32(2):102-6. doi: 10.1016/j.rapm.2006.10.005.
Clinical trial NCT04509258: Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning
Official title: Comparative Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Acute Aluminium Phosphide Poisoning: A Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: the Study Focus to Improve the Standard of Care Used for Aluminuim Phosphide Poisoning and to Save Patients With the Minimal Organ Damage
Keywords: N-acetyl cysteine
Acety L- carnitine
paraffin oil
aluminium phosphide
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Ain Shams University hospitals
First posted: 2020-08-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Aluminium Phosphide is a pesticide used in developing countries to prevent rodents and pests from spoiling the harvested grains. it is presented as tablets which can be administered accidently to humans or for committing suicide. this pesticide is fatal even in small concentration as mortality rate can reach 75- 100% of cases. in this study researchers tried to add some supplements to the routine treatment to improve and decrease the fatality rate.


Eligibility criteria: Inclusion Criteria:

* All adult patients with history of acute intoxication with AlP presented to the Poison Control Center of Ain-Shams University hospitals during the period of the study

Exclusion Criteria:

1. Patients less than 18
2. Patients presented with delay time exceeding 12 hours after acute intoxication.
3. Patients with history of cardiac, renal or hepatic diseases.
4. Patients who show hypersensitivity to NAC, ALCAR or paraffin oil.

Primary outcomes:
measure: mortality rate reduction
timeFrame: 1 year
measure: organ damage reduction
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Poison Control Center of Ain-Shams University hospitals
state: Abbasya
Study officials:
References:
Clinical trial NCT04679558: Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs
Official title: Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-12-22
Enrollment: 22
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study ia conducted to know the antibacterial effect of chlorhexidine on the mouth flora speciallly in adolescent special needs who can't hold the tooth brush properly

Detailed description: This study ia conducted to know the antibacterial effect of chlorhexidine on the mouth flora speciallly in adolescent special needs who can't hold the tooth brush properly cause those have alot of problems concerning the accumulagio. Of plaque and so increased bacteria

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of disability like special needs autism and down syndrome

Exclusion Criteria:

* age below 13

Primary outcomes:
measure: Streptococcus mutans count
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: School
Study officials:
affiliation: Resident
name: Katreen Fouad
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00233558: Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
Official title: Multicentre, Randomised, Open Label Study Comparing a "Scheduled Steroid Reduction Strategy" Versus a Free Steroid Reduction Strategy (Physician's Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Rheumatoid Arthritis
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2005-10-06
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX


Eligibility criteria: Inclusion Criteria:

* Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history
* Subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised ACR criteria

Exclusion Criteria:

* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
* Female subject who is pregnant or breast-feeding or considering becoming pregnant

Primary outcomes:
measure: Corticoid reduction and DAS 28
Secondary outcomes:
measure: Patient reported outcomes
measure: Clinical response indicators
measure: Safety parameters
Other outcomes:
Locations:
city: North Chicago
country: United States
facility: Global Medical Information - Abbott
state: Illinois
Study officials:
affiliation: Abbott
name: Global Medical Information
role: STUDY_DIRECTOR
References:
Clinical trial NCT02529358: Text Message Based Maintenance Intervention
Official title: Evaluation of a Transdiagnostic Text Message Based Maintenance Intervention After Inpatient Cognitive Behavioural Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mental Disorders
Keywords: Maintenance intervention
Text messages
Emotion Regulation
Lead sponsor: Friedrich-Alexander-Universität Erlangen-Nürnberg
Sponsor class: OTHER
Collaborators: name: Philipps University Marburg
First posted: 2015-08-20
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The study presents findings from a randomized clinical trial evaluating the effects of text messages encouraging short emotion regulation exercises on the course of psychopathological symptoms after inpatient treatment for depression. In this context, the study also compares the effectiveness of standardized versus personalized text messages.

Detailed description: Introduction: The importance of aftercare and maintenance intervention to reduce psychopathology, prevent relapses and stabilize the effects of inpatient cognitive behavioral therapy is well proven. In order to attain a high reachability rate among the patients, simple, quick and low cost methods should be used. Modern communication technologies, such as mobile phones provide this opportunity. Therefore, the current study explores how modern communication technologies can be used as a support system in psychotherapy to realize a reduced psychopathology.

Methods: A total of 150 patients participated in a transdiagnostical 6-weeks text messaging maintenance intervention. The text messages were based on emotion regulation skills. The effectiveness of different variants of the text messages was studied in a randomized controlled trial, comparing the impact on the patient's psychopathological outcome to receiving personalized text messages versus standardized text messages.

Eligibility criteria: Inclusion Criteria:

* good knowledge of the german language
* owning a mobile phone

Exclusion Criteria:

* brain damage
* personality disorders

Primary outcomes:
measure: Depressive Symptom load
timeFrame: 6 weeks post treatment (after intervention)
measure: Emotion Regulation Competence
timeFrame: 6 weeks post treatment (after intervention)
Secondary outcomes:
measure: Psychopathological symptomatology
timeFrame: 10 weeks Follow-Up
measure: Depressive Symptom load
timeFrame: 10 weeks Follow-Up
measure: Emotion Regulation Competence
timeFrame: 10 weeks follow up
Other outcomes:
Locations:
city: Bad Arolsen
country: Germany
facility: Schön Klinik
state: Hessen
Study officials:
affiliation: Friedrich-Alexander-Universität Erlangen-Nürnberg
name: Sandra Schlicker, Dipl.-Psych.
role: PRINCIPAL_INVESTIGATOR
affiliation: Friedrich-Alexander-Universität Erlangen-Nürnberg
name: Matthias Berking, Prof. Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT00427258: Study Evaluating MOA-728 Administered in Healthy Men
Official title: An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]MOA-728 in Healthy Men
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Healthy
Keywords: healthy subjects
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2007-01-29
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Absorption, distribution, metabolism, and excretion (ADME) study with 14C in healthy young men.


Eligibility criteria: Inclusion Criteria:

* Men aged 18 to 50 years inclusive at screening.
* Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg. BMI is calculated by taking the subject's weight, in kilograms, divided by the square of the subject's height, in meters, at screening: BMI = weight (kg)/\[height (m)\]2
* Healthy as determined by the investigator on the basis of screening evaluations.
* Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Primary outcomes:
measure: Distribution of drug using radioactive study drug.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Jeff Cohn
role: STUDY_DIRECTOR
References:
Clinical trial NCT00067158: Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1
Official title: Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Tobacco Use Disorder
Keywords: nicotine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2003-08-13
Enrollment: 585
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.


Eligibility criteria: Inclusion Criteria:

* Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

* Patient is psychotic
* Use of smokeless tobacco
* Use of other smoking cessasation product
* Pregnancy
* Patient has hyper-tension, heart problems, or skin condition

Primary outcomes:
measure: Drug use
measure: Smoking Cessation
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Matrix Institute on Addictions
state: California
city: Tarzana
country: United States
facility: Tarzana Treatment Center
state: California
city: Miami
country: United States
facility: SPECTRUM
state: Florida
city: Orlando
country: United States
facility: Center for Drug Free Living
state: Florida
city: Ann Arbor
country: United States
facility: Chelsea Arbor Addictions Treatment Center
state: Michigan
city: Detroit
country: United States
facility: Psychiatry and Behavioral Medicine Professionals I
state: Michigan
city: Long Island City
country: United States
facility: Narco Freedom (Bridge Plaza)
state: New York
city: New York
country: United States
facility: St. Luke's Roosevelt Hospital Center
state: New York
city: New York
country: United States
facility: St. Luke's Roosevelt Hospital Center, Womens
state: New York
city: New York
country: United States
facility: Mount Sinai Medical Center
state: New York
city: Concord
country: United States
facility: Piedmont Behavioral Healthcare
state: North Carolina
city: Wilmington
country: United States
facility: Coastal Horizons Center, Inc.
state: North Carolina
city: Pickens
country: United States
facility: Behavioral Health Services of Pickens County
state: South Carolina
Study officials:
affiliation: New York University
name: Malcolm Reid, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02836158: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Official title: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Primary Central Nervous System Lymphoma
Lead sponsor: Navy General Hospital, Beijing
Sponsor class: OTHER
First posted: 2016-07-18
Enrollment: 100
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).

Detailed description: The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in elderly patients with primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

Exclusion Criteria:

* Involved sites other than the brain, meninges, CSF, or the eyes.
* Age less than 18 years or greater than 75 years.
* Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/L, platelets \<100 ×10\^9/L, and hemoglobin level\< 8 g/dL).
* Known cause of immunosuppression (ie, HIV type I infection).
* Any previous malignancy.
* Creatinine clearance below 60 mL/min.
* Heart insufficiency (NYHA IIIB or IV).
* Uncontrolled infection.
* Noncompensated active pulmonary or liver disease.
* Previously treated for PCNSL, except by corticosteroids.

Primary outcomes:
measure: Overall survival
timeFrame: 3 year Overall survival
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Navy General Hospital
state: Beijing
Study officials:
affiliation: Navy General Hospital, Beijing
name: Liren Qian, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT01069458: The Effect of a High Protein Diet Versus a Low Fat Diet on Body Weight After Smoking Cessation
Official title: The Effect of a High Protein Diet Versus a Low Fat Diet on Body Weight and Composition, Total Energy Expenditure, Metabolic Risk Factors and Eating Behavior After Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Overweight
Obesity
Keywords: Dietary intervention
Smoking cessation
Body weight
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2010-02-17
Enrollment: 122
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether subjects following a high protein diet will gain less in weight after smoking cessation compared to subjects following a low fat diet due to the effects of protein on metabolic rate and hunger.

Detailed description: Sustained smoking cessation is one of the most effective therapies to avoid premature morbidity and mortality. However, weight gain associated with nicotine withdrawal may attenuate some of the beneficial health effects and is cited as a major obstacle to quit smoking. The mechanism for the weight gain is not elucidated but reduced resting metabolic rate, reduced total energy expenditure, increased caloric intake and changes in fat metabolism may be involved. Elucidating effective strategies to prevent or reduce post-cessation weight gain may improve health outcomes of smoking cessation.

Eligibility criteria: Inclusion Criteria:

* Smoking 10 cigarettes per day, BMI 25-40

Exclusion Criteria:

* Recent change in weight, contra-indications to use varenicline, a medication to assist smoking cessation

Primary outcomes:
measure: Body weight and waist circumference
timeFrame: 4 weeks, 3 months and 6 months after smoking cessation
Secondary outcomes:
measure: Resting metabolic rate, total energy expenditure, body composition, components of metabolic syndrome, eating behavior
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Department of Preventive Cardiology
Study officials:
affiliation: Oslo University Hospital
name: Serena Tonstad, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Heggen E, Svendsen M, Tonstad S. Smoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling. Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):335-341. doi: 10.1016/j.numecd.2016.12.011. Epub 2017 Jan 4.
Clinical trial NCT02652858: Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass
Official title: Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiopulmonary Bypass
Cardiac Surgery
Extracorporeal Circulation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
Collaborators: name: Université Joseph Fournier Grenoble 1
First posted: 2016-01-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Central and peripheral arterial pressure decoupling occurs in some clinical conditions like sepsis or cardiopulmonary bypass. This decoupling may leed to unsuitable decisions such as the use of catecholamines.

The aim of this study is to evaluate the pulse wave's speed as a marker of central and peripheral arterial pressure decoupling in a scheduled condition which is the cardiopulmonary bypass during cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* Scheduled patient for coronary or valvular surgery with cardiopulmonary bypass
* Cardiopulmonary bypass is at least 90 minutes
* Written consent is needed

Exclusion Criteria:

* Patient with heart rate disorder
* Patient with aortic dissection
* Dobutamine/milrinone/levosimendan treatment before surgery
* Patient with heart rate due to a pacemaker

Primary outcomes:
measure: Measurement of femoral, radial and humeral pulses during a cardiopulmonary by-pass (CPBP).
timeFrame: Day one (6 times)
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hospices Civils de Lyon
Study officials:
References:
Clinical trial NCT02335658: Long-term Study of DSP-5423P in Patients With Schizophrenia
Official title: Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Lead sponsor: Sumitomo Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-01-12
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.


Eligibility criteria: Inclusion Criteria:

* Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria
* Patients who are aged 18 years or older at informed consent
* Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion Criteria:

* Patients who fall under a contraindication listed in the LONASEN® package insert
* Patients with Parkinson disease, etc.

Primary outcomes:
measure: Adverse Events and Adverse Drug Reactions, Etc.
timeFrame: week 52
Secondary outcomes:
measure: Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week52 and Week 52 Last Observation Carried Forward(LOCF) From DSP-5423P Baseline
timeFrame: Week 52, Week 52 (LOCF)
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: 38 Sites
Study officials:
affiliation: Sumitomo Pharma Co., Ltd.
name: Director, Drug Development Division
role: STUDY_DIRECTOR
References:
citation: Iwata N, Ishigooka J, Naoi I, Matsumoto M, Kanamori Y, Nakamura H, Higuchi T. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study. CNS Drugs. 2020 Jan;34(1):103-116. doi: 10.1007/s40263-019-00692-6.